Administration of prostacyclin prevents ventricular fibrillation following coronary occlusion in conscious dogs
- PMID: 6182407
- DOI: 10.1097/00005344-198209000-00011
Administration of prostacyclin prevents ventricular fibrillation following coronary occlusion in conscious dogs
Abstract
The effects of prostacyclin (PGI2) on ventricular arrhythmias following 20 min of coronary occlusion and release were studied in 34 conscious dogs. We administered PGI2 at 100 ng/kg/min and did not observe significant changes in heart rate, blood pressure, or systemic vascular resistance. During the control period, heart rate was 97 +/- 30 (mean +/- SEM) vs. 99 +/- 28 in the PGI2-treated group. Mean arterial pressure was 115 +/- 26 mm Hg and 109 +/- 10 mm Hg in the control and PGI2 groups, respectively. Systemic vascular resistance declined minimally from 2,985 +/- 221 dyn . s . cm-5 to 2,484 +/- 135 dyn . s . cm-5 during the PGI2 infusion (p = NS). Following coronary occlusion, the frequency of ventricular fibrillation was reduced from 53% (9/17) in the control group to 6% (1/17) in the PGI2 group (p less than 0.01). Overall 80-min postinfarction survival was 64% in the group receiving PGI2 infusion compared to 24% in the control group (p less than 0.05). The effects of PGI2 in preventing ventricular fibrillation following acute coronary occlusion can be ascribed to a direct action of this prostaglandin on the myocardium, rather than to an indirect effect due to a reduction in systemic vascular resistance.
Similar articles
-
Prostacyclin prevents ventricular fibrillation in a canine model of sudden cardiac death.Basic Res Cardiol. 1986 Jan-Feb;81(1):40-53. doi: 10.1007/BF01907426. Basic Res Cardiol. 1986. PMID: 3521579
-
Epoprostenol (PGI2) prevents postischemic ventricular fibrillation and improves outcome in a canine model of sudden death.J Pharmacol. 1985 Apr-Jun;16(2):139-57. J Pharmacol. 1985. PMID: 3903352
-
Effects of prostacyclin (PGI2) on vulnerability to ventricular fibrillation in the normal and ischemic canine heart.Eur J Pharmacol. 1982 May 7;80(1):83-91. doi: 10.1016/0014-2999(82)90180-7. Eur J Pharmacol. 1982. PMID: 7047179
-
The influence of prostacyclin on coronary occlusion induced arrhythmia in cats.Prostaglandins Med. 1979 Sep;3(3):173-84. doi: 10.1016/0161-4630(79)90101-0. Prostaglandins Med. 1979. PMID: 399533
-
Cardioprotection: endogenous protective mechanisms promoted by prostacyclin.Basic Res Cardiol. 1991;86 Suppl 3:215-21. doi: 10.1007/978-3-662-30769-4_21. Basic Res Cardiol. 1991. PMID: 1781766 Review.
Cited by
-
Prostaglandins and the cardiovascular system.Br Heart J. 1983 May;49(5):405-9. doi: 10.1136/hrt.49.5.405. Br Heart J. 1983. PMID: 6340706 Free PMC article. Review. No abstract available.
-
Prostacyclin.J R Soc Med. 1983 Apr;76(4):245-9. doi: 10.1177/014107688307600401. J R Soc Med. 1983. PMID: 6341583 Free PMC article. No abstract available.
-
The Jeremiah Metzger lecture. Participation of eicosanoids in the syndromes of myocardial ischemia.Trans Am Clin Climatol Assoc. 1990;101:154-60. Trans Am Clin Climatol Assoc. 1990. PMID: 2486439 Free PMC article. Review. No abstract available.
-
Nobel lecture, 8th December 1982. Adventures and excursions in bioassay: the stepping stones to prostacyclin.Br J Pharmacol. 1983 Aug;79(4):821-38. doi: 10.1111/j.1476-5381.1983.tb10020.x. Br J Pharmacol. 1983. PMID: 6360277 Free PMC article. Review. No abstract available.
-
Effects of prostacyclin analogue, OP-2507, on function and metabolism in the ischemic working rat heart.J Anesth. 1992 Oct;6(4):446-54. doi: 10.1007/s0054020060446. J Anesth. 1992. PMID: 15278518
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous